Home
About Rico
Company Profile
Development History
Corporate culture
Company environment
Company Honors
News
Company News
Industry Trends
Services
Cooperation
Partner
Contact Us
Policy
Join us
Social Recruitment
Campus Recruitment
CN
EN
National policy
12-17
Administrative Measures for Drug Operation Licenses
(Promulgated by Order No. 6 of the State Food and Drug Administration on February 4, 2004; amended according to the “Decision on Amending Certain Regulations” adopted at the Bureau Meeting of the National Medical Products Administration on November 7, 2017)
12-16
Measures for the Supervision and Administration of Pharmaceutical Production
The “Measures for the Supervision and Administration of Pharmaceutical Production” were reviewed and approved at the 1st Bureau Meeting of the State Administration for Market Regulation on January 15, 2020. They are now promulgated and shall take effect as of July 1, 2020.
Notice Regarding Matters Concerning the Certificate of Pharmaceutical Product Approval (CPP) for Marketing Authorization
Given the FDA’s adjustment to its policy on CPP documents, it is agreed that for FDA-approved drugs exported from countries other than the United States, the CPP document will no longer be required when filing a registration application in China. Instead, applicants may submit a screenshot of the FDA website or other supporting documentation to substantiate the information provided in the registration application.
July 22, 2020
On July 22, 2020, the company name was changed to Rico International (Beijing) Medicine Technology Co., Ltd.
August 26, 2020
On August 26, 2020, the company relocated to Room 709, Building 10, Wanda Plaza, No. 93 Jianguo Road, Chaoyang District, Beijing.
April 15, 2020
April 15, 2020 – Huawei Ruike (Beijing) International Pharmaceutical Technology Co., Ltd. was established.
11-25
Notice from the Center for Drug Evaluation of the National Medical Products Administration on the Issuance of the “Procedures for Supplementing Information by the Center for Drug Evaluation (Trial)” (No. 42 of 2020)
To support the implementation of the “Measures for Drug Registration Management” and further standardize the management of supplementary materials in drug registration review and approval, and drawing on the research findings from the drug review process-oriented scientific management system as well as the practical experience of review work, the Center for Drug Evaluation has developed and issued the “Procedures for Supplementary Materials Work at the Center for Drug Evaluation (Trial).”
11-10
Bringing global pharmaceutical and healthcare products and technologies to China,
Rico International (Beijing) Medicine Technology Co., Ltd. was established in 2020. It is composed of a group of accomplished and highly contributing pharmaceutical experts, scholars, and business management professionals in the pharmaceutical and healthcare fields. The company aims to assist domestic and international pharmaceutical enterprises in product introduction, technology acquisition, and market expansion; to bring global pharmaceutical and healthcare products and technologies into China, enabling Chinese consumers to access cutting-edge and high-quality medicines from around the world, thereby benefiting the Chinese people; and at the same time, to export Chinese pharmaceutical and healthcare products and technologies to overseas counterparts, benefiting all humanity.
Export Chinese pharmaceutical and healthcare products and technologies to international counterparts, benefiting all of humanity.
Aimed at supporting domestic and international pharmaceutical companies in product introduction, technology acquisition, and market expansion.